

Shabnam Shahrokh MD

• Shabnamshahrokh@gmail.com • Shabnamshahrokh@sbm.ac.ir • [ORCID: 0000-0002-3420-5608](#) • [Scholar](#)

Education

2013-2015 Shahid Beheshti University of Medical Sciences, Iran

Fellowship of Gastroenterology and Hepatology – Borad Certified

2008-2012 Tehran University of Medical Sciences, Iran

Internal Medicine Postgraduate Training – Board Certified

1999-2006 Mazandaran University of Medical Sciences, Iran

General physician

Research Interest

• Inflammatory Bowel Disease • Translational Medicine • Gut Microbiome • Clinical Gastroenterology

Special Experiences

Research Positions

Vice-chancellor in research affairs, Research Institute for Gastroenterology and Liver Diseases (RIGLD)

Director of IBD Department at RIGLD

Editorial board and reviewer at Gastroenterology and Hepatology from Bed to Bench

Clinical Positions

Gastroenterology and Hepatology Consultant at Taleghani Hospital

Skills

CLINICAL SKILLS

- Diagnostic and therapeutic endoscopy and coloscopy
- Balloon enteroscopy
- Video capsule endoscopy
- EMR
- Clinical supervisor of advanced GI fellowship program for IBD
- Cell therapy for IBD

LABROTORY TEACHNIQUES

- Cell culture
- PCR and RT-PCR and primer design

PERSONAL SKILLS

- Teamwork
- Team lead and leadership
- Networking

TEACHING

- Mentoring and teaching

RESEARCH SKILL

- Research planning and Design

Awards and Honors

• Best researcher of 2022 in the gastroenterology field at 23rd Abu Reyhan Bironi National Research Festival

- Identified as an Exceptional Talent by National Elites Foundation
- Scientific Chair of Iranian Congress of Gastroenterology and Hepatology 2022

Selected Publications

Publication Summary: H-index: 21; i-10 index: 38; Scopus Articles: 95 Link to: [Scholar](#); [WOS](#); [Scopus](#)

1. Nemati, S., ..., Shahrokh, et al. Evaluation of the mTORC activity in the presence of *Toxoplasma gondii* and azathioprine in human monocyte cell line. *BMC microbiology*, 2023. <https://doi.org/10.1186/s12866-023-02819-8>
2. Gholam-Mostafaei, ..., Shahrokh, S, et al. Intestinal microbiota changes pre-and post-fecal microbiota transplantation for treatment of recurrent *Clostridioides difficile* infection among Iranian patients with concurrent inflammatory bowel disease. *Frontiers in Microbiology*. 2023. doi.org/10.3389/fmicb.2023.1147945
3. Salarieh, N, ..., Shahrokh, S*. Characterization of the mucosal microbiota in patients with nodular lymphoid hyperplasia with concurrent irritable bowel syndrome compared to healthy controls. *Molecular Biology Reports*. 2023. doi.org/10.1007/s11033-022-07974-1
4. Hatamnejad, , ..., Shahrokh, S*. Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. *Frontiers in Medicine*. 2023. doi.org/10.3389/fmed.2022.1008711
5. Khosravi, ..., Shahrokh, S, et al. Characterisation of extracellular vesicles isolated from hydatid cyst fluid and evaluation of immunomodulatory effects on human monocytes. *Journal of Cellular and Molecular Medicine*. 2023. <https://doi.org/10.1111/jcmm.17894>
6. Heydari, .., S., Shahrokh, et al. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*. 2023. doi.org/10.1093/ibd/izad219
7. Hatamnejad MR, Shahrokh S*, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. *Front Immunol*. 2022. doi: 10.3389/fimmu.2022.980189.
8. Rajabnia M, Shahrokh S*, et al. Obesity, a challenge in the management of inflammatory bowel diseases. *Immunol Res*. 2022. doi: 10.1007/s12026-022-09315-7.
9. Ghavami SB, Shahrokh S*, et al. Serological response to SARS-CoV-2 is attenuated in patients with inflammatory bowel disease and can affect immunization. *JGH Open*. 2022. doi: 10.1002/jgh3.12725.
10. Shahrokh S, et al. High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. *Arch Physiol Biochem*. 2022 doi: 10.1080/13813455.2022.2080228.
11. Salarieh N, Shahrokh S*, et al. Characterization of the mucosal microbiota in patients with nodular lymphoid hyperplasia with concurrent irritable bowel syndrome compared to healthy controls. *Mol Biol Rep*. 2022. doi: 10.1007/s11033-022-07974-1.
12. Nadalian B, Shahrokh S, et al. Phylogrouping and characterization of *Escherichia coli* isolated from colonic biopsies and fecal samples of patients with flare of inflammatory bowel disease in Iran. *Front Med (Lausanne)*. 2022. doi: 10.3389/fmed.2022.985300.
13. Ghorbaninejad M, Shahrokh S, et al. Inhibition of epithelial SHH signaling exerts a dual protective effect against inflammation and epithelial-mesenchymal transition in inflammatory bowel disease. *Toxicol In Vitro*. 2022. doi: 10.1016/j.tiv.2022.105382.
14. Khoramjoo SM, Shahrokh S, et al. Overview of Three Proliferation Pathways (Wnt, Notch, and Hippo) in Intestine and Immune System and Their Role in Inflammatory Bowel Diseases (IBDs). *Front Med (Lausanne)*. 2022 May 23;9:865131. doi: 10.3389/fmed.2022.865131.
15. Morshedzadeh N, Shahrokh S, et al. Nutritional management of inflammatory bowel disease; an overview of the evidences. *Diabetes Metab Syndr*. 2022. doi: 10.1016/j.dsx.2022.102440.
16. Abdehagh M, Shahrokh S*, et al. Serum procalcitonin levels associate with *Clostridioides difficile* infection in patients with inflammatory bowel disease. *BMC Infect Dis*. 2021. doi: 10.1186/s12879-021-06804-2.
17. Shahrokh S, et al. Efficacy and Safety of Melatonin as an Adjunctive Therapy on Clinical, Biochemical, and Quality of Life in Patients with Ulcerative Colitis. *Iran J Pharm Res*. 2021. doi: 10.22037/ijpr.2020.113822.14508.
18. Hossein-Khannazer N, Shahrokh S, et al. Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results. *Hum Cell*. 2021. doi: 10.1007/s13577-021-00560-w.

19. Morshedzadeh N, Shahrokh S, et al. The effects of flaxseed supplementation on metabolic syndrome parameters, insulin resistance and inflammation in ulcerative colitis patients: An open-labeled randomized controlled trial. *Phytother Res.* 2021. doi: 10.1002/ptr.7081.
20. Heidarian F, Shahrokh S*, et al. Altered fecal bacterial composition correlates with disease activity in inflammatory bowel disease and the extent of IL8 induction. *Curr Res Transl Med.* 2019. doi: 10.1016/j.retram.2019.01.002.
21. Balaii H, Shahrokh S*, et al. Determining the degree of adherence to treatment in inflammatory bowel disease patients. *Gastroenterol Hepatol Bed Bench.* 2018. doi: 10.22037/ghfbb.v0i0.1541
22. Asadzadeh Aghdaei H, Shahrokh S*, et al. Detailed analysis of total colectomy on health-related quality of life in adult patients with ulcerative colitis. 2017. doi: 10.22037/ghfbb.v0i0.1296

References

M.R. Zali, M.D., FACG, FAGA: Professor of Gastroenterology; President of Research Institute for Gastroenterology & Liver Disease (RIGLD), Tehran, Iran; E-mail: nnzali@hotmail.com; Phone: +98-21-22432525.

N. Naderi, M.D: Associate Professor of Gastroenterology; E-mail: n_naderi@yahoo.com; Phone: +98-21-22432525

H. Asadzadeh, M.D: Associate Professor of Gastroenterology; E-mail: hamid.assadzadeh@gmail.com; Phone: +98-21-22432525